Skip to main content

Table 3 Proportion of patients achieving ≥ 4-point reductions in SGRQ total score, by baseline characteristics

From: Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials

  Mepolizumab   Placebo
ITT population
 Patients with ≥ 4-point reduction in SGRQ total score, n (%) 335/466 (72)   256/465 (55)
 Odds ratio (mepolizumab/placebo), 95% CI; p-value   2.17 (1.63, 2.87); p < 0.001  
Age at asthma onset: < 18 years
 Patients with ≥ 4-point reduction in SGRQ total score, n (%) 90/130 (69)   65/122 (53)
 Odds ratio (mepolizumab/placebo), 95% CI   1.95 (1.12, 3.38)  
Age at asthma onset: 18–< 40 years
 Patients with ≥ 4-point reduction in SGRQ total score, n (%) 123/173 (71)   96/171 (56)
 Odds ratio (mepolizumab/placebo), 95% CI   2.17 (1.34, 3.51)  
Age at asthma onset: ≥ 40 years
 Patients with ≥ 4-point reduction in SGRQ total score, n (%) 121/162 (75)   95/172 (55)
 Odds ratio (mepolizumab/placebo), 95% CI   2.80 (1.70, 4.62)  
Lung function: ≤ 60% predicted FEV1
 Patients with ≥ 4-point reduction in SGRQ total score, n (%) 171/243 (70)   132/242 (55)
 Odds ratio (mepolizumab/placebo), 95% CI   2.13 (1.44, 3.16)  
Lung function: > 60–80% predicted FEV1
 Patients with ≥ 4-point reduction in SGRQ total score, n (%) 137/177 (77)   98/176 (56)
 Odds ratio (mepolizumab/placebo), 95% CI   3.03 (1.84, 4.99)  
Lung function: ≥ 80% predicted FEV1
 Patients with ≥ 4-point reduction in SGRQ total score, n (%) 27/46 (59)   26/47 (55)
 Odds ratio (mepolizumab/placebo), 95% CI   2.12 (0.70, 6.48)  
  1. CI confidence interval, FEV1 forced expiratory volume in 1 s, ITT intent-to-treat, SGRQ St George’s Respiratory Questionnaire